Short treatment with sofosbuvir and ledipasvir over only 6 weeks is sufficient to cure acute hepatitis C (HCV)
A pilot study presented today found that all patients with acute HCV who were treated with a direct-acting antiviral treatment over a ‘short-duration’ of six weeks had undetectable HCV after a 12 week follow-up. The investigator-initiated study, presented at The International Liver CongressTM in Barcelona, Spain, demonstrated that the combination of sofosbuvir and ledipasvir for only six weeks is sufficient to treat patients with acute HCV.
Those infected with HCV usually develop acute Hepatitis C, which spontaneously clears in 10 to 50% of infected persons. Early diagnosis of HCV infection is rare and the disease may go unnoticed until patients have already developed serious liver damage.1 Sofosbuvir and ledipasvir is one possible regimen for treatment of patients with chronic HCV. Sustained virologic response (SVR) is greater than 95% with a 12-week course of this treatment.2
“Given the high cost of sofosbuvir and ledipasvir, and the associated side effects that occur during treatment, we set out to assess whether shortened treatment duration could be an effective option for acute Hepatitis C patients,” said Katja Deterding from Hannover Medical School, Germany and study author. “Our research demonstrates that not only is the combination of sofosbuvir and ledipasvir safe, well tolerated and effective in acute HCV genotype 1 patients who have severe liver disease with very high liver enzymes, but a shorter treatment duration does not appear to hinder efficacy,” confirmed Professor Heiner Wedemeyer, the senior author of this study.
The German pilot study, performed by the German HepNet Study-House included 20 patients. Risk factors of HCV infection among the study members included; sexual transmission (n=11), medical procedures/needle stick injury (n=5), drug use (n=1), and nail treatment complications (n=1). The causes were unspecified for the remaining two patients.
All 20 patients completed six weeks of sofosbuvir and ledipasvir without ribavirin. At the 12 week follow up, all 20 patients had undetectable HCV and achieved SVR (100%). Fatigue was the most frequent side effect reported by study members (30%).
“These exciting findings open up short and cost-effective treatment options that could prevent the spread of HCV in high risk populations,” said Professor Frank Tacke, EASL Governing Board member. “We look forward to seeing this pilot study extended so the findings can be validated and then hopefully used as a tool to change clinical practice for the better.”
The Latest on: Hepatitis C
via Google News
The Latest on: Hepatitis C
- Expanded Classification of Hepatitis C Virus Into 7 Genotypes and 67 Subtypes: Updated Criteria and Genotype Assignment Web Resourceon October 12, 2021 at 8:25 am
The 2005 consensus proposal for the classification of hepatitis C virus (HCV) presented an agreed and uniform nomenclature for HCV variants and the criteria for their assignment into genotypes and ...
- Woman with Hepatitis C spits in deputy's eye during ER ruckuson October 11, 2021 at 5:15 pm
A Crossville woman whom authorities said was being disruptive at the emergency room in Cumberland Medical Center earlier this month has been arrested and charged with felony assault on a first ...
- Have you been tested for Hepatitis C? There’s a good chance you need to beon October 9, 2021 at 11:00 pm
A Richland County Sheriff’s deputy’s recent exposure to Hepatitis C presents a good opportunity to catch up on this potentially deadly blood-born disease. The good news is that up to 35 ...
- Antios Therapeutics to Participate in H.C. Wainwright 2nd Annual Hepatitis B Virus Conferenceon October 7, 2021 at 4:42 am
Antios Therapeutics at the H.C. Wainwright 2nd Annual Hepatitis B Virus (HBV) Virtual Conference Presentation Details: Fireside Chat: Wednesday, October 13, 2021, at 1:30 p.m. ET Presenters: Gregory ...
- Newsom signs bills to broaden STD testing, hepatitis screeningson October 5, 2021 at 2:15 pm
Governor Gavin Newsom signed two bills addressing sexually transmitted diseases into law October 4. The first deals with the epidemics of chlamydia, gonorrhea and syphilis. The second facilitates ...
- Hepatitis C Screening Paired With Mammography (Mammo'C)on October 4, 2021 at 5:00 pm
SCREENING FOR THE HEPATITIS C VIRUS BY TROD PAIRED WITH MAMMOGRAPHY AND MANAGEMENT OF CHRONIC HEPATITIS C IN WOMEN AGED 50 TO 74 IN THE AGGLOMERATION OF MONTPELLIER Description: Number of women who ...
- Hepatitis C virus infection is associated with the development of hepatocellular carcinoma.on October 4, 2021 at 1:52 pm
A possible causative role for the recently discovered hepatitis C virus (HCV) in the development of hepatocellular carcinoma (HCC) was investigated by assay of sera from HCC patients in Japan for ...
- Hepatitis C virus prevalence in Belgiumon October 3, 2021 at 4:59 pm
Reliable hepatitis C prevalence estimates are crucial for a good follow-up of the indicators to eliminate hepatitis by 2030 as set by the World Health Organization. In Belgium, no recent national ...
- Pregnant With Hep C? Here’s What You Need To Knowon September 29, 2021 at 9:14 am
Are you Hep C positive and pregnant? Here's what you need to know about how the virus may affect your pregnancy and what your options are.
- Vancouver-based Molecular Testing Labs unveils hepatitis C teston September 28, 2021 at 10:45 pm
Vancouver-based Molecular Testing Labs announced Tuesday it will release a new hepatitis C test that uses dried blood samples from finger pricks rather than an intravenous blood draw. The test is ...
via Bing News